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Case report A 36-year-old Irish joiner was referred with recurrent dysplastic and neoplastic skin lesions on sun exposed sites. Nine years previously he had received a cadaver renal allograft, and, for the 6 years before referral to our unit, he had suffered multiple solar keratoses on his hands and face, and Bowen's disease and squamous cell carcinomas on the backs of his hands. These had been treated with cryotherapy, topical 5-fluorouracil and 8 lesions had been excised, one with a skin graft. He had been on conventional immunosuppression since his transplant and was taking prednisolone 10 mg and azathioprine 150 mg daily.
On examination he had 4 tumours and multiple solar keratoses on the backs of his hands ( Figure 1 ). One of these was excised and histological examination showed it to be an invasive squamous cell carcinoma. He was started on etretinate 1 mg/kg daily and within a week developed marked regression in the size of the tumours and disappearance of the keratoses. When the etretinate was stopped however, the keratoses started to recur within a fortnight. On restarting the etretinate at a dose of0.75 mg/kg daily the keratoses resolved completely and he has developed no new dysplastic lesions.
Discussion
In 1971 Walder et al' reported from Australia that 7 out of 51 renal allograft recipients developed a total of 19 skin neoplasms between 4 and 45 months after transplantation. They also noted that many oftheir patients had viral warts, particularly on sun-exposed sites. Studies from Glasgow2, Leicester3 and Cardiff' have shown that substantial numbers of renal transplant patients in Britain have skin problems. The prevalence of dysplastic epidermal lesions was up to 25%4, and up to 53% of patients had viral warts4. Fungal skin infections and herpes zoster were also significantly more common in renal allo-graft recipients2.
The development of dysplastic skin lesions increases with the time since transplantation5, and is directly related to excess sun exposure2. Experiments in mice have shown that exposure to ultraviolet radiation not only causes mutations that may lead to skin cancers but also alters the immune system in specific ways to make the host tolerant to the tumour6. Human papilloma virus (HPV)-5 had initially been identified only in tumours from patients with epidermodysplasia verruciformis, a rare condition in which squamous cell carcinomas are prone to develop from the numerous warts present mainly on sun-exposed sites7. It has since been found in some skin tumours from renal allograft recipients and a recent study found HPV-5 in 30 tumours from 10 such patients8. Lennard et al.3 found that renal allograft recipients with dysplastic lesions had a statistically significantly higher level of the active azathioprine metabolite 6-thioguanine nucleotide in their red cells than did matched controls. This suggests that chemical carcinogenesis may be a factor contributing to the development of skin tumours. All the above studies have been carried out on patients on conventional immunosuppression with azathioprine and prenisolone, whilst medern regimens use cyclosporin, often in combination with azathioprine and! or prednisolone. It is tco soon to tell whether patients on cyclosporin will have the same incidence of skin tumours as patients on conventional immunosuppression, but skin neoplasms have been reported in patients exposed to cyclosporin alone9. A 5-year follow-up of 34 transplant patients in a trial comparing cyclosporin alone with azathioprine and steroids, found that in the cyclosporin group one patient developed a squamous cell carcinoma and one a basal cell carcinoma, whilst in the control group one patient developed a squamous cell carcinoma. Experiments in mice have shown that cyclosporin, prednisolone and azathioprine all inhibit normal repair of ultraviolet irradiation-induced DNA lesions in epidermal keratinocytes10.
Retinoids have been used for a variety of conditions such as xeroderma pigmentosum and basal cell naevus syndrome and have been shown to inhibit the development of, and induce regression of, skin neoplasms"1. Dermatologists have been reluctant to use them in allograft recipients as animal experiments have shown that retinoids promote skin graft rejection in mice'. However, Shuttleworth et aL03 used etretinate in 6 renal allograft recipients with recurrent skin tumours and found that 5 ofthe patients responded, although 2 developed tumours within 6 months of stopping treatment. None showed any impairment of graft function. In some patients the long-term use ofretinoids causes abnormalities of bone, including osteoporosis14, a cause for concern when a patient is already on steroids.
Our patient illustrates the problems of a young immunosuppressed patient with recurrent skin neoplasms. He has obtained a good clinical response to etretinate, although started to relapse on stopping treatment. He has had no impairment of his renal function and is being carefully monitored for the side effects, of retinoids, particularly to bone.
